RxDoctor Payments Data

Chona Santos Miranda, MD

Family Medicine · Egg Harbor City, NJNPI 1457383549

Payments from drug & device makers

$624in general payments, 2019–2025

Across 19 payments — averaging $32.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • Pfizer$214
  • Novo Nordisk$118
  • Dexcom, Inc.$17
  • Lilly USA, LLC$14
  • Amarin Pharma, Inc.$12

What the payments were for

  • Food & beverage$624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624 in reported general payments places this provider in the 55th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$160,584
Medicare patients
318
Services billed
2,762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$118,563
JardianceEmpagliflozin118$96,181
MounjaroTirzepatide70$94,429
FarxigaDapagliflozin Propanediol88$81,899
RybelsusSemaglutide13$27,115
EliquisApixaban31$20,532
MyrbetriqMirabegron19$19,415
TradjentaLinagliptin20$13,049
VascepaIcosapent Ethyl12$12,074
Rosuvastatin Calcium298$7,930
LyricaPregabalin12$6,973
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,161
Atorvastatin Calcium399$4,344
SynthroidLevothyroxine Sodium70$4,199
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$4,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$118$145,67996 claims
Lilly USA, LLCMounjaro$14$94,42970 claims
AstraZenecaFarxiga$250$81,89988 claims
PfizerEliquis, Lyrica$214$27,50543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Egg Harbor City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →